Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 0.46% | 74.10 | 0.0% | $2395.49m | |
| NVAX | Novavax, Inc. | 1.67% | 170.29 | 99.2% | $1218.87m | |
| SRNE | Sorrento Therapeutics, Inc. | 5.95% | 14.42 | 1.8% | $598.67m | |
| GILD | Gilead Sciences, Inc. | 0.79% | 69.35 | 1.0% | $559.14m | |
| AMGN | Amgen, Inc. | -0.36% | 240.69 | 1.3% | $476.61m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.16% | 620.21 | 2.5% | $429.51m | |
| BNTX | BioNTech SE | -0.10% | 77.00 | 0.0% | $399.56m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.13% | 272.99 | 1.9% | $368.45m | |
| BIIB | Biogen, Inc. | 10.10% | 305.71 | 1.6% | $361.06m | |
| ILMN | Illumina, Inc. | -10.94% | 355.66 | 3.5% | $336.82m | |
| VXRT | Vaxart, Inc. | 1.05% | 9.19 | 0.0% | $280.99m | |
| EBS | Emergent BioSolutions, Inc. | 2.91% | 130.66 | 6.4% | $180.62m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.60% | 103.28 | 2.0% | $166.60m | |
| SGEN | Seattle Genetics, Inc. | -0.83% | 160.45 | 6.0% | $163.01m | |
| IBIO | iBio, Inc. | -6.65% | 3.79 | 0.2% | $158.51m |
Company Profile
Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.